Current status of the cost burden of first-line systemic treatment for patients with advanced hepatocellular carcinoma in Japan, 2021-22.
Hiroshi ImaokaKeita SasakiRyunosuke MachidaHiroaki NaganoSohei SatoiMasafumi IkedaSatoshi KobayashiTaro YamashitaTakuji OkusakaAkio IdoEtsuro HatanoHaruo MiwaMasaki UenoKazuhiko NakaoSatoshi ShimizuHidekazu KuramochiRyotaro SakamoriHidetaka TsumuraNaohiro OkanoKazuhiko ShiojiHirofumi ShirakawaNoriyuki AkutsuKunihiro TsujiHiroshi IshiiKumiko UmemotoAkinori AsagiMakoto Uenonull nullPublished in: Japanese journal of clinical oncology (2024)
Advances in systemic therapies for HCC have led to prolonged patient survival. However, the treatment costs are also increasing, imposing a burden on both the patients and society.